The workgroup wanted to address the problem of variability in how bioinformatics pipelines are validated in order to improve the accuracy of NGS tests.

Geisinger is hoping to help others around the country implement precision medicine, which requires significant investment in genomics expertise, as well as infrastructural and operational changes.

The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.

Factors like the country's interest in multiplexed dx panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said a Sciex official.

Factors like the country's interest in multiplexed dx panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said a Sciex official.